Suppr超能文献

肺炎球菌蛋白 D 结合疫苗(PHiD-CV)对马来西亚国家免疫规划的经济影响。

Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme.

作者信息

Aljunid Syed, Maimaiti Namaitijiang, Ahmed Zafar, Muhammad Nur Amrizal, Md Isa Zaleha, Azmi Soraya, Sulong Saperi

机构信息

International Institute for Global Health, United Nations University, Kuala Lumpur, Malaysia; Faculty of Medicine, International Centre for Case-Mix and Clinical Coding, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

International Institute for Global Health, United Nations University, Kuala Lumpur, Malaysia; Faculty of Medicine, Department of Community Health, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

出版信息

Value Health Reg Issues. 2014 May;3:146-155. doi: 10.1016/j.vhri.2014.04.008. Epub 2014 May 21.

Abstract

OBJECTIVE

To assess the cost-effectiveness of introducing pneumococcal polysaccharide and nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in the National Immunization Programme of Malaysia. This study compared introducing PHiD-CV (10 valent vaccine) with current no vaccination, as well as against the alternative 13-valent pneumococcal conjugate vaccine (PCV13).

METHODS

A lifetime Markov cohort model was adapted using national estimates of disease burden, outcomes of pneumococcal disease, and treatment costs of disease manifestations including pneumonia, acute otitis media, septicemia, and meningitis for a hypothetical birth cohort of 550,000 infants. Clinical information was obtained by review of medical records from four public hospitals in Malaysia from the year 2008 to 2009. Inpatient cost from the four study hospitals was obtained from a diagnostic-related group-based costing system. Outpatient cost was estimated using clinical pathways developed by an expert panel. The perspective assessed was that of the Ministry of Health, Malaysia.

RESULTS

The estimated disease incidence was 1.2, 3.7, 70, and 6.9 per 100,000 population for meningitis, bacteremia, pneumonia, and acute otitis media, respectively. The Markov model predicted medical costs of Malaysian ringgit (RM) 4.86 billion (US $1.51 billion) in the absence of vaccination. Vaccination with PHiD-CV would be highly cost-effective against no vaccination at RM30,290 (US $7,407) per quality-adjusted life-year gained. On comparing PHiD-CV with PCV13, it was found that PHiD-CV dominates PCV13, with 179 quality-adjusted life-years gained while saving RM35 million (US $10.87 million).

CONCLUSIONS

It is cost-effective to incorporate pneumococcal vaccination in the National Immunization Programme of Malaysia. Our model suggests that PHiD-CV would be more cost saving than PCV13 from the perspective of the Ministry of Health of Malaysia.

摘要

目的

评估在马来西亚国家免疫规划中引入肺炎球菌多糖和不可分型流感嗜血杆菌蛋白D结合疫苗(PHiD-CV)的成本效益。本研究将引入PHiD-CV(10价疫苗)与当前不接种疫苗的情况进行了比较,同时也与替代的13价肺炎球菌结合疫苗(PCV13)进行了对比。

方法

采用终身马尔可夫队列模型,利用马来西亚全国疾病负担估计数、肺炎球菌疾病结局以及包括肺炎、急性中耳炎、败血症和脑膜炎在内的疾病表现的治疗成本,对一个假设的550,000名婴儿出生队列进行分析。通过回顾2008年至2009年马来西亚四家公立医院的病历获取临床信息。四家研究医院的住院费用来自基于诊断相关组的成本核算系统。门诊费用使用专家小组制定的临床路径进行估算。评估的视角是马来西亚卫生部的视角。

结果

脑膜炎、菌血症、肺炎和急性中耳炎的估计疾病发病率分别为每100,000人口1.2、3.7、70和6.9例。马尔可夫模型预测,在不接种疫苗的情况下,医疗费用为48.6亿马来西亚林吉特(15.1亿美元)。接种PHiD-CV相对于不接种疫苗具有很高的成本效益,每获得一个质量调整生命年的成本为30,290马来西亚林吉特(7,407美元)。在将PHiD-CV与PCV13进行比较时,发现PHiD-CV优于PCV13,可获得179个质量调整生命年,同时节省3500万马来西亚林吉特(1087万美元)。

结论

在马来西亚国家免疫规划中纳入肺炎球菌疫苗接种具有成本效益。我们的模型表明,从马来西亚卫生部的角度来看,PHiD-CV比PCV13更节省成本。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验